Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Cancer or amyloidosis?

ESH 2016 - 3rd International Conference on Multiple Myeloma

Published: 2 Nov 2016

Views: 3511

Rating:

Save

Dr Giovanni Palladini - Director, Amyloidosis Research and Treatment Center, Pavia, Italy

Dr Palladini talks to ecancertv at ICMM 2016 about screening for amyloidosis, to prevent people being mistakenly treated for cancer.

Because amyloidosis is rare, he says, it can be overlooked as a possibility and people can undergo futile chemotherapy.

ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

SABCS 2023: Latest breast cancer diagnostics guidelines

Prof Nadia Harbeck and Prof Giuseppe Curigliano

SABCS 2023: Latest breast cancer diagnostics guidelines ( Prof Nadia Harbeck and Prof Giuseppe Curigliano )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Genomic testing: Awareness and effective communication between healthcare...

Prof Richard Simcock and Antonella Cardone

Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

EGFR mutations in NSCLC - from biomarker to treatment selections in second line

Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo

EGFR mutations in NSCLC - from biomarker to treatment selections in second line ( Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo )

More from ecancer